Regarding therapies, the PANTHER-IPF clinical trial2 was conducted in carriers of the aforementioned MUC5B and TOLLIP variants to evaluate their modulatory effect on immunosuppressive and antioxidant treatments. This evidence concerns the gene TOLLIP and idiopathic pulmonary fibrosis.